9/9/2024
The potential of mRNA-based medicine extends beyond vaccines against infectious diseases, offering promise for personalized treatments like cancer vaccines and gene therapy. However, common challenges in mRNA manufacturing for advanced therapies include long turnaround times for template DNA production and dsRNA impurity levels in the drug substance. Kudo Bio and LineaRx have collaborated to provide a solution for these challenges by establishing a seamless, cell-free process for mRNA-LNP manufacturing using the novel Linea™ IVT platform. This platform combines enzymatically produced IVT templates with the proprietary Linea™ RNAP polymerase. In this seminar, Kudo Bio and LineaRx will present proof-of-concept study data and a case study demonstrating how the Linea™ IVT platform can support rapid dsRNA-mitigated mRNA manufacturing.
Speakers:
Aaron Chung, Director, Nucleic Acid Platforms
Aaron Chung is the Director of Nucleic Acid Platforms at LineaRx, an Applied DNA Sciences company. He is the co-inventor of LineaRx’s RNA polymerase, Linea™ RNAP, a specialized enzyme that aims to overcome the critical challenges of traditional mRNA manufacturing, such as reducing dsRNA impurities and accelerating production timelines.
Atsuko Sangria, PhD
Director, Drug Substance Process Development
Atsuko has 16 years of research experience in molecular biology and vaccine development. Before joining Kudo Bio, Atsuko led mRNA drug substance (DS) process development, scale-up, and technology transfer at RVAC Medicines. Previously, she was an expert scientist at GSK Vaccines, where she played a vital role in mRNA vaccine platform development. Atsuko obtained her Ph.D. in Pharmaceutical Sciences from Kitasato University in Japan.
Best regards,
The Kudo Biotechnology and Applied DNA Sciences Teams!
Check video below:
